Indication:
1. First line treatment in newly diagnosed Ph+ CML-CP
- The effectiveness of Nilonix (Nilotinib) is based on major molecular response and cytogenetic response rates.
- The recommended dose of Nilonix (Nilotinib) is 300 mg orally twice daily.
2. Resistant or Intolerant Ph+ CML-CP & CML-AP
- The effectiveness of Nilonix (Nilotinib) is based on hematologic and cytogenetic response rates.
- The recommended dose of Nilonix (Nilotinib) is 400 mg orally twice daily.
Strength & dosage form:
- 150 mg Capsule
